The State of Lung Cancer Research: A Global Analysis

Introduction: Lung cancer is the leading cause of years of life lost because of cancer and is associated with the highest economic burden relative to other tumor types. Research remains at the cornerstone of achieving improved outcomes of lung cancer. We present the results of a comprehensive analysis of global lung cancer research between 2004 and 2013 (10 years). Methods: The study used bibliometrics to undertake a quantitative analysis of research output in the 24 leading countries in cancer research internationally on the basis of articles and reviews in the Web of Science (WoS) database. Results: A total of 32,161 lung cancer research articles from 2085 different journals were analyzed. Lung cancer research represented only 5.6% of overall cancer research in 2013, a 1.2% increase since 2004. The commitment to lung cancer research has fallen in most countries apart from China and shows no correlation with lung cancer burden. A review of key research types demonstrated that diagnostics, screening, and quality of life research represent 4.3%, 1.8%, and 0.3% of total lung cancer research, respectively. The leading research types were genetics (20%), systemic therapies (17%), and prognostic biomarkers (16%). Research output is increasingly basic science, with a decrease in clinical translational research output during this period. Conclusions: Our findings have established that relative to the huge health, social, and economic burden associated with lung cancer, the level of world research output lags significantly behind that of research on other malignancies. Commitment to diagnostics, screening, and quality of life research is much lower than to basic science and medical research. The study findings are expected to provide the requisite knowledge to guide future cancer research programs in lung cancer.

[1]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[2]  P Roe,et al.  How do the media report cancer research? A study of the UK's BBC website , 2008, British Journal of Cancer.

[3]  Roger Collier,et al.  Rapidly rising clinical trial costs worry researchers , 2009, Canadian Medical Association Journal.

[4]  M. Frydenberg,et al.  Evidence of increasing mortality with longer diagnostic intervals for five common cancers: a cohort study in primary care. , 2013, European journal of cancer.

[5]  Xiaomei Ma,et al.  Global Burden of Cancer , 2006, The Yale journal of biology and medicine.

[6]  L. Holmberg,et al.  Social inequalities in non-small cell lung cancer management and survival: a population-based study in central Sweden , 2010, Thorax.

[7]  Max Dahele,et al.  Management of early-stage non-small cell lung cancer using stereotactic ablative radiotherapy: controversies, insights, and changing horizons. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[8]  Matthijs Oudkerk,et al.  Prospects for population screening and diagnosis of lung cancer , 2013, The Lancet.

[9]  Mark D. Huffman,et al.  Global Cardiovascular Research Output, Citations, and Collaborations: A Time-Trend, Bibliometric Analysis (1999–2008) , 2013, PloS one.

[10]  Ping Yang,et al.  Lung cancer in China: challenges and interventions. , 2013, Chest.

[11]  J. Samet,et al.  Epidemiology of lung cancer. , 1994, Chest.

[12]  M. Slater,et al.  News Coverage of Cancer in the United States: A National Sample of Newspapers, Television, and Magazines , 2008, Journal of health communication.

[13]  M. Coleman,et al.  Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study. , 2014, The Lancet. Oncology.

[14]  Gemma Derrick,et al.  Democratising research evaluation: Achieving greater public engagement with bibliometrics-informed peer review , 2013 .

[15]  Jane C Weeks,et al.  End-of-life discussions, goal attainment, and distress at the end of life: predictors and outcomes of receipt of care consistent with preferences. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  María E. Len-Ríos,et al.  Study Asks if Reporter's Gender or Audience Predict Paper's Cancer Coverage , 2008 .

[17]  Amy Y. Chen,et al.  Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis. , 2008, The Lancet. Oncology.

[18]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[19]  J. Collin.  Tobacco control, global health policy and development: towards policy coherence in global governance , 2012, Tobacco Control.

[20]  D. Parkin.  The global burden of cancer. , 1998, Seminars in cancer biology.

[21]  Nobhojit Roy,et al.  The Global Burden of Cancer 2013. , 2015, JAMA oncology.

[22]  R. Peto,et al.  Global effects of smoking, of quitting, and of taxing tobacco. , 2014, The New England journal of medicine.

[23]  R. Hubbard,et al.  What characteristics of primary care and patients are associated with early death in patients with lung cancer in the UK? , 2014, Thorax.

[24]  R. Sullivan,et al.  The media and cancer: education or entertainment? An ethnographic study of European cancer journalists , 2014, Ecancermedicalscience.

[25]  P. Dhillon,et al.  Evidence-informed frameworks for cost-effective cancer care and prevention in low, middle, and high-income countries. , 2014, The Lancet. Oncology.

[26]  E. Davies,et al.  Coverage of common cancer types in UK national newspapers: a content analysis , 2014, BMJ Open.

[27]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[28]  N. Hawkes.  UK must improve its recruitment rate in clinical trials, report says , 2012, BMJ : British Medical Journal.

[29]  Alona Muzikansky,et al.  Early palliative care for patients with metastatic non-small-cell lung cancer. , 2010, The New England journal of medicine.

[30]  W. Curran,et al.  Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. , 2015, The Lancet. Oncology.

[31]  Grant Lewison,et al.  The definition of biomedical research subfields with title keywords and application to the analysis of research outputs , 1996 .

[32]  Grant Lewison,et al.  The classification of biomedical journals by research level , 2004, Scientometrics.

[33]  V. Rusch,et al.  Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial , 2009, The Lancet.

[34]  Richard Sullivan,et al.  Economic burden of cancer across the European Union: a population-based cost analysis. , 2013, The Lancet. Oncology.

[35]  J. Williamson,et al.  How does the media profile of cancer compare with prevalence? , 2011, Annals of the Royal College of Surgeons of England.

[36]  M. Provencio,et al.  New molecular targeted therapies integrated with radiation therapy in lung cancer. , 2010, Clinical lung cancer.

[37]  M. Parmar,et al.  Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an open-label, pragmatic, randomised controlled trial , 2015, The Lancet Respiratory Medicine.

[38]  R. Govindan,et al.  Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[39]  Ludo Waltman,et al.  Field-Normalized Citation Impact Indicators and the Choice of an Appropriate Counting Method , 2015, ISSI.

[40]  Bernard Rachet,et al.  Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004–2007 , 2013, Thorax.

[41]  M. Ezzati,et al.  Effects of smoking and solid-fuel use on COPD, lung cancer, and tuberculosis in China: a time-based, multiple risk factor, modelling study , 2008, The Lancet.

[42]  Concepción S. Wilson,et al.  The Literature of Bibliometrics, Scientometrics, and Informetrics , 2001, Scientometrics.

[43]  Michael Thomas,et al.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.

[44]  Grant Lewison,et al.  Trends in the global funding and activity of cancer research , 2008, Molecular oncology.

[45]  Fiona A. Stewart,et al.  Strategies to improve radiotherapy with targeted drugs , 2011, Nature Reviews Cancer.

[46]  Christopher W. Jones,et al.  Non-publication of large randomized clinical trials: cross sectional analysis , 2013, BMJ.